Product Disclosures

Reflecting standard oncology practice, which often requires the off-label or investigational use of some products, this educational activity includes information about many drugs. All faculty participating in continuing education activities are expected to disclose the approved or investigational status (related to the subject matter of this publication—gynecologic cancers) of all products and devices under discussion. This information, as of the time of printing, is summarized briefly in the table below. In addition, primary references and full prescribing information should be consulted for complete information. Clinicians have the professional responsibility to ensure that drugs are prescribed and used appropriately, based on their own clinical judgment and accepted standards of care.

Generic Name Brand Name Investigational for Gynecologic Cancers FDA Approved for Gynecologic Cancers FDA Approved for Other Uses
Carboplatin Paraplatin   X X
Cisplatin Platinol   X X
Docetaxel Taxotere X   X
Doxorubicin Adriamycin   X X
Etoposide VePesid; Toposar X   X
Gemcitabine Gemzar X   X
Paclitaxel Taxol   X X
Pegylated liposomal doxorubicin Doxil   X X
Topotecan Hycamtin   X X
Vinorelbine Navelbine X   X

Adapted from Drug Facts and Comparisons. St Louis, Mo: Facts & Comparisons; 2005.